Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported ...

Moby Strategic Execution and Safety Management. Management attributes the 2025 performance to rapid enrollment in the H ...

A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

Results from ADAPT OCULUS are expected to support a sBLA submission to the FDA to secure a label expansion for oMG.

Learn more about whether Celldex Therapeutics, Inc. or Zai Lab Limited is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

International equities added another 5% in the fourth quarter, finishing up more than 30% for the year, the largest gain ...

Researchers at the University of Basel have developed a gene therapy that could potentially treat a rare and currently fatal ...

Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported ...

Duke researchers study an approach that may help millions manage diabetic neuropathy and chemotherapy-induced nerve pain.

Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 12:00 PM ESTCompany ParticipantsBrett ...

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half ...